Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
OneSource Specialty Pharma Ltd, Adani Ports & Special Economic Zone Ltd, Graphite India Ltd, DLF Ltd are among the other stocks to see a surge in volumes on BSE today, 09 September 2026.
Biocon Ltd clocked volume of 168.67 lakh shares by 10:45 IST on BSE, a 75.68 times surge over two-week average daily volume of 2.23 lakh shares. The stock gained 1.55% to Rs.398.65. Volumes stood at 1.22 lakh shares in the last session.
OneSource Specialty Pharma Ltd saw volume of 6.91 lakh shares by 10:45 IST on BSE, a 34.12 fold spurt over two-week average daily volume of 20246 shares. The stock dropped 2.59% to Rs.1,545.05. Volumes stood at 86505 shares in the last session.
Adani Ports & Special Economic Zone Ltd witnessed volume of 60.3 lakh shares by 10:45 IST on BSE, a 21.52 times surge over two-week average daily volume of 2.80 lakh shares. The stock increased 2.75% to Rs.1,755.80. Volumes stood at 3.15 lakh shares in the last session.
Graphite India Ltd witnessed volume of 15.49 lakh shares by 10:45 IST on BSE, a 17.56 times surge over two-week average daily volume of 88204 shares. The stock increased 16.60% to Rs.856.40. Volumes stood at 56869 shares in the last session.
DLF Ltd witnessed volume of 33.45 lakh shares by 10:45 IST on BSE, a 15.02 times surge over two-week average daily volume of 2.23 lakh shares. The stock dropped 1.23% to Rs.667.65. Volumes stood at 9.14 lakh shares in the last session.
Biocon announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country's Productive Development Partnership (PDP) program.
The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab.
The PDP provides the consortium exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. It also supports the long term adoption of Biocon's product within Brazil's public oncology network.
Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period. As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.
This agreement would mark an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country’s productive development partnership (PDP) program.
Pertuzumab is a monoclonal antibody used in the treatment of HER2-positive breast cancer. Currently, the product is not manufactured locally in Brazil and is a significant expenditure for the country's Unified Health System (SUS).
Bahiafarma is a public pharmaceutical laboratory of the State of Bahia, Brazil, focused on pharmaceutical research, technological development, innovation and the production and supply of medicines and other health products, particularly for Brazil’s SUS.
Bionovis is a Brazilian biotechnology company focused on developing, manufacturing and commercializing complex biological medicines and biosimilars, with a strong emphasis on technology transfer, local biopharmaceutical manufacturing and expanding access to advanced therapies in Brazil.
The PDP provides the consortium exclusive access to Brazil’s public healthcare market, which accounts for approximately 70% of the country’s demand for Pertuzumab. It also supports the long term adoption of Biocon’s product within Brazil’s public oncology network.
As part of the PDP framework, the product will undergo phased localization in Brazil in the mid to long term.
Biocon will receive milestone payments and a share of revenues generated from the Brazil PDP opportunity over a 10-year period.
Shreehas Tambe, CEO & managing director, Biocon, said: 'Brazil is an important country for Biocon, and our journey here reflects the transformative potential of strong partnerships in building local capabilities and expanding access to high-quality, affordable medicines.
This long-term supply contract for Pertuzumab marks a significant milestone in this journey, enabling us to reach more patients living with HER2-positive breast cancer and address an important healthcare need at scale.'
Biocon is India’s leading biopharma company. It is fully integrated and delivers biopharma solutions ranging from discovery to development and commercialisation. It has diversified revenue streams covering biosimilars, contract research, small molecules and APIs.
The company had reported 355% jump in consolidated net profit to Rs 141 crore in Q1 FY27 from Rs 31 crore in Q1 FY26. Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
The scrip rose 0.99% to currently trade at Rs 397.40 on the BSE.
The product, a biosimilar to Neulasta, is developed and manufactured by Biocon Biologics, parent entity of Biocon Biologics UK PLC, with Global Regulatory Partners Japan serving as the marketing authorization holder on behalf of Biocon. Sandoz K.K. shall exclusively promote, sell, and distribute the product in Japan.
Pegfilgrastim is a prescription injection used to lower the risk of infection in people receiving strong cancer chemotherapy or those exposed to high doses of radiation.
'This approval further strengthens Biocon’s portfolio of biosimilar products in Japan and reaffirms the company’s commitment to increasing patient access to high-quality and affordable medications globally,' the company said in a statement.
The scrip shed 0.28% to currently trade at Rs 408.85 on the BSE.
Biocon's subsidiary in the United States has received supplemental U.S. Food and Drug Administration (FDA) approval for Yesintek® 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek® 90 mg/ml single-dose prefilled autoinjector.
Yesintek® was originally approved by the U.S. FDA on 29 November 2024. The Yesintek® single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek® is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn's disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
Yesintek was originally approved by the U.S. FDA on 29 November 2024.
The Yesintek single-dose prefilled autoinjector offers patients with another important treatment option. This new delivery format supports more tailored treatment approaches across different care settings and patient needs.
Yesintek is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adult and pediatric patients 6 years of age and older, and moderate to severely active Crohn’s disease and ulcerative colitis in adults—a range of debilitating autoimmune conditions that affects tens of thousands of Americans.
'This supplemental approval enhances Biocon’s comprehensive portfolio of immunology products in the United States and reaffirms the company’s commitment to improving access to affordable medicines for patients around the world,' the company said in a statement.
The scrip rose 0.30% to currently trade at Rs 413.35 on the BSE.
Shares of Life Insurance Corporation of India (LIC) are banned from F&O trading on 6 August 2026.
New listing:
MV Electrosystems will make its stock market debut today. The Rs 290-crore IPO was offered in a price band of Rs 400–425 per share. The issue received bids for 75.30 crore shares against 39.87 lakh shares on offer, resulting in an overall subscription of 188.85 times.
Juniper Green Energy is also set to debut on the bourses today. The company's Rs 1,800-crore IPO, priced in the Rs 214–225 per share band, received bids for 46.96 crore shares against 5.89 crore shares on offer, translating into an overall subscription of 7.97 times.
Earnings Today:
Life Insurance Corporation of India (LIC), Hero MotoCorp, Britannia Industries, Lupin, Samvardhana Motherson International, Apollo Tyres, Blue Star, Fortis Healthcare, Crompton Greaves Consumer Electricals, Bosch Home Comfort India, Premier Energies, NCC, Emcure Pharmaceuticals, EIH, Aegis Logistics, PG Electroplast, Firstsource Solutions, Signatureglobal (India), RateGain Travel Technologies, Campus Activewear will declare their quarterly results later today.
Stocks to Watch:
Aurobindo Pharma reported 28.11% jump in consolidated net profit to Rs 1,056.56 crore in Q1 FY27 compared with Rs 824.75 crore in Q1 FY26. Revenue from operations climbed 16.30% YoY to Rs 9,150.35 crore in Q1 FY27.
PB Fintech (Policy Bazaar)’s consolidated net profit jumped 92.54% to Rs 162.89 crore on 40.08% increase in revenue from operations to Rs 1,888.28 crore in Q1 FY27 over Q1 FY26.
Biocon’s consolidated net profit surged 872.27% to Rs 142.35 crore in Q1 FY27, compared with Rs 36.76 crore in Q1 FY26. Net sales jumped 10% YoY to Rs 4,336 crore in Q1 FY27.
Neuland Laboratories reported 962.37% surge in consolidated net profit to Rs 147.67 crore in Q1 FY27 compared with Rs 13.9 crore posted in year-ago period. Net sales soared 119.16% YoY to Rs 641.58 crore in the quarter ended 30th Jun 2026.
Bikaji Foods International's consolidated net profit edged up 0.4% YoY to Rs 60.14 crore in Q1 FY27, compared with Rs 59.90 crore a year ago. Net sales grew 12.5% YoY to Rs 734.26 crore.
JK Lakshmi Cement reported 29.60% decline in standalone net profit to Rs 106.77 crore in Q1 FY27 from Rs 151.67 crore in Q1 FY26. Net sales rose 9.41% YoY to Rs 1,904.78 crore in Q1 FY27.
Revenue from operations rose by 10% year-on-year (YoY) to Rs 4,336 crore during the period under review.
Biopharma (Biosimilars + Generics) revenue grew 17% YoY in the first quarter, driven by momentum from recent biosimilar and generic product launches across key markets. Biosimilars revenue increased 16% YoY to Rs 2,855 crore and Generics revenue increased 21% YoY Rs 760 crore in Q1 FY27.
Services revenue decreased 16% YoY to Rs 736 crore in Q1 FY27 due to continued impact of challenges faced last year.
Net R&D expenses for Q1 FY27 added up to Rs 240 crore, up 17% YoY.
While EBITDA improved by 7% YoY to Rs 902 crore, EBITDA margin remained stable at 21% in the June'26 quarter.
Profit before tax in Q1 FY27 stood at Rs 128 crore, up 32% from Rs 97 crore in Q1 FY26.
The company has recorded a net tax credit of Rs 92 crore for the June'26 quarter. It had reported a net tax outgo of Rs 77 crore in the same period last year.
Kiran Mazumdar-Shaw, executive chairperson, Biocon, said: 'Biocon has entered FY27 with a clear focus on translating our strategic investments into sustainable growth and long-term value creation.
A favourable policy environment for biosimilars together with our expanded manufacturing capabilities in the U.S. reinforce our confidence in the long-term opportunities across North America, our biggest market.
We also remain confident that the investments in new capabilities at our research services business will support its next phase of growth.'
Biocon announced the commercial launch of Yesafili™ (aflibercept-jbvf) in the United States. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various types of ophthalmology conditions, is a biosimilar of its reference product EYLEA® (aflibercept) 2 mg. The product was approved previously and granted interchangeable designation* by the U.S. Food and Drug Administration in May 2024, allowing substitution at the pharmacy level in accordance with state laws.
Shreehas Tambe, CEO & Managing Director, Biocon Ltd., said, “The launch of Yesafili™️ in the U.S. marks an important step in expanding the global availability of biosimilar Aflibercept 2 mg for patients with eye conditions. This milestone further strengthens our presence in ophthalmology and builds on our FDA approval as one of the first interchangeable biosimilars to Eylea®️ 2 mg, advancing access to life-changing medicines for patients around the world.”